IDXX IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.…
Industry Peers
Diagnostics & ResearchKey Statistics
About IDEXX Laboratories (NASDAQ: IDXX)
›
IDEXX Laboratories (NASDAQ: IDXX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 11,000 employees.
The shares were at 689.65 USD on 19 November 2026, down 3.4% over 52 weeks. Its 52-week range is 500.61 USD to 769.98 USD: the price is 10.4% below the high and 37.8% above the low.
At a market capitalisation of 54.33B USD, it trades at 46.5 times trailing earnings and 40.8 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 34.9, a premium of 33% for IDXX.
IDEXX Laboratories reports return on equity of 66.0%, an operating margin of 32.5% and revenue up 9.9% year over year.
Its debt exceeds its cash by 775.43M USD, a debt-to-equity ratio of 0.61. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 717.17 USD is 4.0% above the current price. The next earnings report is expected on 1 February 2027.